Chiesi

The US first-approver advantage over the European Union remains stark, with eight of ten novel agents first cleared by the US Food and Drug Administration, according to a Pink Sheet analysis of rece

As the legal saga between Astellas and two generics firms Lupin and Zydus reached its culmination just a few weeks ago, Lupin’s CEO Vinita Gupta said the company feels certain about the opportun

The US FDA approved six novel agents over the first three weeks of May, representing the work of six different review different divisions. The new approvals account for a little more than a quarter of

The annual J.P. Morgan Healthcare Conference reunited biopharma investors, executives and stakeholders in San Francisco for the first time since 2020 and while attendees embraced the face-to-face inte